Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

137/433 Matches for
“non-alcoholic fatty liver disease NAFLD”

“non-alcoholic fatty liver disease NAFLD” Clear all
  1. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 100

    FibroTest SteatoTest Metabolic

  2. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 100

    …developing complications of end-stage liver disease. Although it lacks sensitivity, ultrasonography…

    ActiTest FibroTest NashTest SteatoTest +1

  3. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 100

    …commonly recommended for nonalchoholic fatty liver disease (NAFLD) patients. However, there is…

    SteatoTest Metabolic

  4. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 99

    …of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar…

    FibroTest Alcohol HBV HCV +1

  5. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 99

    …well validated in non-alcoholic fatty liver disease (NAFLD) than in patients…

    ActiTest FibroTest SteatoTest Metabolic

  6. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 99

    FibroTest Metabolic

  7. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 98

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  8. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 98

    …assessment of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is…

    FibroTest Metabolic

  9. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 98

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  10. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 97

    liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD); however…

    FibroTest Metabolic

  11. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 97

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  12. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 96

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  13. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 96

    …consequences on liver injury compared with CHC and NAFLD. ### Methods Patients with…

    FibroTest SteatoTest HBV HCV +1

  14. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 96

    …characterize patients with nonalcoholic fatty liver disease (NAFLD). A multicenter study was…

    ActiTest FibroTest NashTest SteatoTest +1

  15. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 95

    Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  16. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 95

    …high risk of nonalcoholic fatty liver disease. Noninvasive tests of steatosis, nonalcoholic…

    FibroTest NashTest SteatoTest HIV

  17. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 95

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  18. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 94

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD

    FibroTest NashTest SteatoTest Metabolic

  19. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 94

    …and quantification in nonalcoholic fatty liver disease (NAFLD). ### Methods Cross-sectional study…

    SteatoTest Metabolic

  20. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 94

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  21. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 93

    …spectroscopy), fatty liver index score, non-alcoholic fatty liver disease fibrosis score…

    FibroTest NashTest Metabolic

  22. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 93

    ActiTest AshTest FibroTest NashTest +6

  23. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 92

    …risk factor for non-alcoholic fatty liver disease (NAFLD) occurrence and progression…

    NashTest SteatoTest Metabolic

  24. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 92

    …of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol…

    FibroTest Other

  25. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 92

    …factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and its implication…

    FibroTest NashTest SteatoTest Metabolic

  26. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 91

    FibroTest Metabolic

  27. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 91

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  28. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 91

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  29. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 90

    liver-related prognosis in patients with non-alcoholic fatty liver disease (NAFLD

    FibroTest Metabolic

  30. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 90

    ActiTest FibroTest NashTest-2 Metabolic

  31. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 90

    non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver

    FibroTest Alcohol HBV HCV +1

  32. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 89

    …standard for assessing nonalcoholic fatty liver disease (NAFLD) histologic lesions in patients…

    FibroTest NashTest SteatoTest Metabolic

  33. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 89

    …one hand and non-alcoholic fatty liver disease (NAFLD) on the other…

    ActiTest FibroTest NashTest SteatoTest +1

  34. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 88

    fatty liver disease with liver biopsy, blood fibrosis tests (Nonalcoholic Fatty Liver

    FibroTest Metabolic

  35. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 88

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The…

    FibroTest Metabolic

  36. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 88

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease

    FibroTest Metabolic

  37. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 87

    …B virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  38. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 87

    …nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer…

    FibroTest SteatoTest Metabolic

  39. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 87

    …0.74-0.74) in presumed NAFLD to 0.91 (95% CI…

    NashTest-2 SteatoTest-2 Metabolic

  40. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 86

    …histologic lesions of non-alcoholic fatty liver disease (NAFLD). The aim was…

    NashTest Metabolic

  41. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 86

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  42. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 86

    FibroTest Alcohol HBV HCV +3

  43. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 85

    …The rate of adoption of non-invasive diagnostic tests for liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  44. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 85

    …measured using the non-invasive FibroTest(®). ### Results Advanced liver fibrosis (stage F2…

    FibroTest Metabolic

  45. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 84

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  46. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 84

    alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and…

    FibroTest Alcohol HBV HCV +1

  47. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 84

    …CAP was significantly correlated with SteatoTest, Fatty Liver Index (FLI), percentage of…

    SteatoTest Metabolic

  48. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 83

    …4 (FIB-4), non-alcoholic fatty liver disease fibrosis score (NFS), body…

    FibroTest Metabolic

  49. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 83

    liver disease (59.6%) and chronic hepatitis B (52.9%). Liver biopsy…

    FibroTest Alcohol HBV HCV +3

  50. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 83

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  51. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 82

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  52. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 82

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  53. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

    Codjia T et al. · Obes Surg · 2021 Match 82

    …therapeutic options for non-alcoholic fatty liver disease (NAFLD), affecting 90% of…

    FibroTest NashTest SteatoTest Metabolic

  54. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 81

    alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). The…

    FibroTest Alcohol HBV HCV +2

  55. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 81

    …FIB4, BARD, and nonalcoholic fatty liver disease scores. A combination of NIT…

    FibroTest NashTest SteatoTest Metabolic

  56. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 80

    …Utility of non-invasive markers of liver fibrosis has been proved in…

    FibroTest

  57. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 80

    …We reviewed the landmark studies in metabolic liver disease, sources of the…

    ActiTest FibroTest NashTest NashTest-2 +3

  58. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 80

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  59. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 79

    …Multiple non-invasive methods of liver fibrosis assessment have been developed, but…

    FibroTest HBV HCV HIV

  60. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

    Ivancovsky-Wajcman D et al. · Dig Liver Dis · 2019 Match 79

    …protective potential in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), there…

    FibroTest NashTest SteatoTest Metabolic

  61. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 79

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  62. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 78

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  63. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 78

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions in…

    ActiTest FibroTest NashTest SteatoTest +1

  64. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 78

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  65. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 77

    …both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in…

    FibroTest Alcohol HBV HCV +3

  66. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 77

    …All patients in the cohort except 1 were managed without a liver

    FibroTest NashTest

  67. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

    Ducancelle A et al. · J Clin Gastroenterol · 2017 Match 76

    …C (CHC) and non-alcoholic fatty liver disease (NAFLD). Therefore, we compared…

    FibroTest Alcohol HBV HCV +2

  68. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.

    Istaces N et al. · Clin Biochem · 2015 Match 76

    …F3 liver fibrosis stages in non-alcoholic fatty liver disease with 34…

    FibroTest HBV HCV

  69. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 76

    …97 with alcoholic liver disease (ALD), and 223 non-ALD, were included…

    FibroTest SteatoTest Alcohol

  70. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 75

    …ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest…

    FibroTest Metabolic

  71. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 75

    …B (HBV) non alcoholic (NAFLD) and alcoholic (ALD) fatty liver diseases. This…

    FibroTest Alcohol HBV HCV +3

  72. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review

    Kovalic AJ et al. · Eur J Gastroenterol Hepatol · 2023 Match 75

    fatty liver disease (NAFLD). Due to well-documented flaws associated with liver

    FibroTest Metabolic

  73. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 74

    …this algorithm in nonalcoholic fatty liver disease (NAFLD). ### Approach And Results One…

    FibroTest Metabolic

  74. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 74

    …hepatitis nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD). Neither…

    ActiTest FibroTest SteatoTest Alcohol +5

  75. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 73

    …B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were…

    SteatoTest Alcohol HBV HCV +1

  76. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 73

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  77. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 73

    FibroTest Metabolic

  78. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 72

    …male gender, older age, and NAFLD as a cause of liver disease

    FibroTest Alcohol HBV HCV +3

  79. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 72

    …nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However…

    FibroTest NashTest-2 Metabolic

  80. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 72

    FibroTest Metabolic

  81. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 71

    …silybum marianum on non alcoholic fatty liver disease (NAFLD). ### Methods In 72…

    SteatoTest Metabolic

  82. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 71

    liver diseases such as viral hepatitis and nonalcoholic fatty liver disease (NAFLD

    FibroTest Alcohol

  83. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 71

    …Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement…

    FibroTest Metabolic

  84. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 70

    …chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and…

    ActiTest FibroTest Alcohol HBV +3

  85. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 70

    …UK Biobank with apparently healthy liver participants (middle-aged, n=138,125…

    FibroTest

  86. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 69

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  87. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 69

    …the early spread of coronavirus disease 2019 (Covid-19) in the general…

    FibroTest COVID

  88. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 69

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver

    FibroTest Alcohol HBV HCV +1

  89. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 68

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  90. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 68

    disease in those patients with non-alcoholic fatty liver disease (NAFLD) by…

    ActiTest FibroTest NashTest SteatoTest +1

  91. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 68

    …tests in patients with metabolic liver disease (MASLD). An unmet need is…

    FibroTest-T2D Metabolic

  92. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 67

    …The assessment of the degree of liver fibrosis in alcoholic liver disease

    FibroTest Alcohol

  93. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 67

    …fibrosis in patients with alcoholic liver disease recruited from primary and secondary…

    FibroTest Alcohol

  94. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 67

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  95. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 66

    liver biopsy. In this review, we discuss the application of these non

    FibroTest Alcohol HBV HCV +1

  96. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 66

    liver disease (MASLD) are linked to the development of peripheral artery disease

    ActiTest FibroTest NashTest SteatoTest +1

  97. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 65

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  98. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 65

    …the interpretation of non-invasive biomarkers in liver fibrosis. A scoring system…

    ActiTest FibroTest SteatoTest Alcohol +5

  99. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 65

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  100. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 64

    liver disease severity. ### Objective To compare the awareness of liver disease severity…

    ActiTest FibroTest Alcohol HBV +3

  101. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 64

    …The same results were observed after stratification on APAP cases and non

    ActiTest FibroTest Other

  102. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 64

    FibroTest HCV

  103. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 63

    …Conclusions In patients with chronic liver disease the LCR1 and LCR2 tests…

    LCR1 LCR2 Alcohol HBV +4

  104. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 63

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  105. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 63

    …and ninety patients with chronic liver disease of miscellaneous causes were included…

    FibroTest Alcohol HBV HCV +2

  106. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 62

    ActiTest FibroTest Alcohol HBV +3

  107. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 62

    …fibrosis in patients with chronic liver disease. This paper aims to assess…

    FibroTest Alcohol HBV HCV +3

  108. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 61

    Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis…

    FibroTest Metabolic

  109. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 61

    …between heart disease and metabolic-dysfunction-associated steatotic liver disease (MASLD); however…

    FibroTest Metabolic

  110. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 61

    …For the diagnosis of non-cirrhotic stages, the results were heterogeneous. ### Conclusions…

    FibroTest Alcohol HBV HCV +3

  111. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 60

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  112. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 60

    …various aspects of liver fibrosis relevant to disease patterns and clinical practice…

    FibroTest SteatoTest HBV HCV +1

  113. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 60

    FibroTest Other

  114. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 59

    FibroTest Metabolic

  115. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 59

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  116. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 59

    ActiTest AshTest FibroTest NashTest +7

  117. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 58

    FibroTest Other

  118. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 58

    …AshTest is an appropriate non-invasive alternative to transjugular liver biopsy.

    AshTest Alcohol

  119. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 57

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  120. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 57

    …To evaluate the association between anthropometric measurements and advanced liver disease in…

    ActiTest FibroTest HCV

  121. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 57

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  122. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 56

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  123. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 56

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  124. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 56

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  125. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 55

    …These consisted of 29 healthy volunteers and 35 patients with chronic liver

    ActiTest FibroTest Alcohol HBV +3

  126. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 55

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  127. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 55

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  128. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 54

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  129. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 54

    …Aims To assess Fibroscan for non-invasive diagnosis of asymptomatic liver fibrosis…

    FibroTest Alcohol

  130. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 53

    …virus (HCV) infection or non-HCV-related liver diseases. ### Methods And Results…

    FibroTest Alcohol HBV HCV +2

  131. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 53

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  132. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 53

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  133. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 52

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  134. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 52

    …In HBV and non-alcoholic steatohepatitis (NASH) patients, its performance was poor…

    FibroTest HBV HCV HIV +1

  135. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 52

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  136. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 51

    FibroTest Alcohol

  137. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 51

    …development of alcohol-related liver disease (ALD). Liver biopsy may be used…

    FibroTest Alcohol

Showing the full result list. The page is server-rendered and not paginated.